SITE003-0224

SITE003 (CAN) › SITE003-0224

SITE003-0224

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-05-21

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-08 (study day 8); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.